First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

YANTAI, China I April 8, 2025 I On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and ...

Cytora's proprietary oral mucosa stem cells treatment holds potential to be a game changer in the field of stem cell therapy ...

ISELIN, NJ, USA I April 08, 2025 I Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for ...

SAINT HERBLAIN, France and SCHLIEREN, Zurich I April 9, 2025 I Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech ...

RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – ...

BUSAN, South Korea I April 09, 2025 I NexThera Co., Ltd. (CEO:SaeGwang Park) announced on April 9th that it has completed the first patient enrollment for its ...

OXFORD, UK I April 9, 2025 I Infinitopes Ltd today announces that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Clinical Trial ...

SAN DIEGO, CA, USA & BERLIN, Germany I April 03, 2025 I Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a ...

This milestone marks Context’s second active clinical trial, following the dosing of the first patient in the CTIM-76 trial earlier this year. CTIM-76 is a Claudin 6 (“CLDN6”) x CD3 TCE bispecific ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone ...

ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases ...